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Abstract: We describe three cases of submacular hemorrhage that occurred two to four days 
after anti-VEGF intravitreal injection for occult choroidal neovascularisation in age-related 
macular degeneration and their management with 25 gauge pars plana vitrectomy with injection 
of subretinal recombinant tissue plasminogen activator (rTPA) followed by fluid-air exchange 
and postoperative prone position. Vitrectomy, subretinal rTPA injection and fluid-gas exchange 
apply as a safe and effective treatment in these cases. Functional results seem to be positive 
especially if surgical treatment is promptly performed.
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Introduction
We describe three cases of submacular hemorrhage (SMH) that occurred two to four 
days after anti-vascular endothelial growth factor (anti-VEGF) intravitreal injection 
for occult choroidal neovascularisation (CNV) in age related macular degeneration1 
(AMD) and their management.
Methods
Almost 2500 anti-VEGF intravitreal injections for neovascular AMD were performed 
in our Department between January 2007 and December 2009. Three patients devel-
oped an acute SMH after the injection involving most of the macular region. Fundus 
fluorescein angiography (FFA), indocyanine green angiography (ICGA) and optical 
coherence tomography (OCT) were carried out. After diagnosis, patients underwent 
25 gauge pars plana vitrectomy with posterior hyaloid removal. An injection of 0.2 mL 
of subretinal recombinant tissue plasminogen activator (rTPA) (125 µg/mL) through a 
41-gauge flexible translocation microcannula (DORC-dual bore BSS injection needle 
0.1 mm tip) followed.2 The rTPA was injected inferiorly to the SMH in order to create 
a bullous retinal detachment encompassing the entire blood clot. Finally a fluid-air 
exchange was performed and patients maintained a supine position for 45 minutes 
followed by a postoperative prone position.
Case 1
In January 2008, a 67-year old woman with 20/20 visual acuity and metamorphopsia in 
her right eye (RE) had been treated for seven months with an injection of ranibizumab Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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each month for an occult CNV . The FFA performed at that 
time demonstrated, in the RE, a paramacular pigment epi-
thelial detachment of 8.07 mm2 and a serous neuroepithelial 
detachment involving the fovea (Figure 1). Four days after 
the 8th intravitreal anti-VEGF injection a SRH developed 
and the visual acuity dropped to light perception. The patient 
underwent surgical treatment the day after the appearance of 
the hemorrhage. No intraoperative or postoperative compli-
cations occurred. A complete displacement of submacular 
hemorrhage from the fovea was obtained. Visual acuity one 
month after treatment rose to 20/63 with metamorphopsia. 
The patient had four further intravitreal injections of beva-
cizumab between May 2008 and August 2008. Significant 
cataract developed which required extraction in August 2008. 
One year following cataract surgery the patient’s visual acuity 
was stable at 20/63.
Case 2
An 84-year old woman, affected by cardiac arrhythmia treated 
with amiodarone, presented in January 2008 complaining of 
metamorphopsia in her RE. An occult CNV due to AMD was 
identified and she underwent three intravitreal bevacizumab 
injections in the RE. In April 2008 her visual acuity was 
20/125 in the RE and 20/63 in the left eye (LE), and the FFA 
and ICGA demonstrated an occult choroidal neovascularisa-
tion of 18.55 mm2 in the LE. Two days after the first intravitreal 
injection of bevacizumab, she developed a thick SMH and 
her visual acuity decreased to hand motion. Two days after 
the hemorrhage occurred, she underwent surgical treatment. 
No intra or postoperative complications were observed. Four 
days after surgery the hemorrhage was displaced from the 
fovea. The visual acuity in the LE one month after treatment 
was 20/160 with metamorphopsia. Two months after surgery 
she underwent another bevacizumab injection in the LE. Her 
visual acuity remained 20/160 for the following year.
Case 3
In June 2007 a 72-year old woman, who had already under-
gone in her RE four ranibizumab injections for a wet AMD, 
started complaining of metamorphopsia in her LE with a 
visual acuity of 20/20. FFA and ICGA demonstrated a lesion 
area of 4.15 mm2 due to occult CNV . A ranibizumab intravit-
real injection was carried out in her LE and two days after a 
SMH occurred (Figure 2). The visual acuity in the LE dropped 
to counting fingers. Two days later she underwent surgical 
treatment. No intraoperative complications were noticed. 
Four days after treatment an almost complete displacement of 
the hemorrhage was achieved. Visual acuity was 20/160 one 
month after surgery and she underwent another ranibizumab 
injection. One year after surgery (Figure 3) her visual acuity 
was unmodified and no other treatment was performed.
Discussion
Submacular hemorrhage is not a rare complication during the 
natural history of occult neovascularisation in AMD. It has 
been reported that it occurs in 17.0% of AMD cases with the 
presence of retinal pigment epithelial detachment (PED).3 
This complication has been also described after photody-
namic therapy especially in cases of AMD with PED.4–9 In our 
Figure 2 submacular hemorrhage of case 3 pre-treatment. Figure 1 Fundus fluorescein angiography of case 1. The DEP area is measured in mm2.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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cases only in one of the three patients was a PED present 
before the treatment (case 1). In that case the area involving 
the PED was 8.07 mm 2 (Figure 1).
Recently a few studies have described the occurrence of 
large submacular hemorrhages after the intravitreal injec-
tion both of bevacizumab and ranibizumab. Karagiannis has 
hypothesized that this event might also be due to changing 
from bevacizumab to ranibizumab.10 In the cases that we 
report, only one kind of anti-VEGF was injected in each 
patient before the occurrence of the hemorrhage.
The mechanism of submacular hemorrhage in these cases 
remains unknown, but it has been hypothesized that the 
contraction of the neovascular membrane could lead to new 
vessels rupturing, especially in large lesions.11,12 In addition, 
a reduction of tight junctions in retinal pigment epithelial and 
endothelial cells related to the decrease in VEGF availability 
could promote the vessel rupture,13 even though recently Peng 
et al have demonstrated that permeability and selectivity 
of the junctions are not affected by VEGF, bevacizumab or 
ranibizumab.14
Vascular endothelial growth factor regulates crucial 
processes, such as embryo- and organogenesis as well as 
immune system, endocrinology, hematopoiesis, (lymphoid) 
vessel architecture and reparative processes in adults.15,16 
It might be therefore expected that its inhibition could 
cause multiple adverse effects. Although the intravitreal 
administration of smaller doses can drastically reduce sys-
temic exposure, and current and past clinical trials do not 
provide sufficient statistical power when evaluating whether 
systemic events significantly differ between the treatment 
and control groups,17–21 possible local side effects on retinal 
perfusion and survival of neuronal tissue must be taken into 
consideration.22
Goverdhan and Lochhead1 has described four cases of 
submacular hemorrhage after intravitreal bevacizumab all 
occurring in large neovascular lesions and the same find-
ing was described by Baeteman et al reporting six cases of 
submacular hemorrhage after ranibizumab injection.23 In 
these series the hemorrhages developed at a median of 14 
to 25 days after the anti-VEGF injection, while in our cases 
the median was 2.6 days.
Moreover it is interesting to note that the patient described 
in our third case developed a large subretinal hemorrhage 
after the injection but the initial lesion was relatively small 
and no PED was noticed.
The occurrence of submacular hemorrhage has been 
also related to anticoagulant therapy and to increased blood 
pressure.24–26 In our series no patients had history of systemic 
hypertension or anticoagulant treatment.
The toxicity of subretinal blood to the neurosensory retina 
has been demonstrated in clinical studies27 and in animal 
models.28 Possible mechanisms of blood-induced retinotox-
icity include mechanical effects such as fibrotic shearing of 
photoreceptors, hypoxia, and metabolic disruption imposed 
by the clot as a diffusion barrier. Direct neurotoxicity seems 
to be induced by the migration of blood components, such 
as iron, to the photoreceptor layer.29
The management of submacular hemorrhage has evolved 
greatly during the past 15 years. A variety of therapeutic 
approaches have been developed, all with the common goal 
of clearing the submacular blood to minimize permanent 
damage to the photoreceptors and retinal pigment epithelium. 
Many options have been proposed including intravitreal 
gas injection;30,31 pars plana vitrectomy and submacular 
surgery, both with and without the assistance of rTPA;32–38 
intravitreal injection of gas and pneumatic displacement of 
the submacular hemorrhage with associated intravitreal injec-
tion of rTPA;39–41 pars plana vitrectomy; subretinal injection 
of r-TPA and fluid gas exchange;42 pars plana vitrectomy 
and subretinal rTPA injection, followed by evacuation 
of the liquefied blood through a 500 µm retinotomy with 
the aid of perfluorocarbon compression of the overlying 
retina;43 intravitreal anti-VEGF;44 combined rTPA, expansile 
gas and bevacizumab;45 and co-application of rTPA and 
  bevacizumab.46 Many procedures include the use of rTPA. 
Subretinal rTPA has recently been demonstrated to achieve 
best anatomical results than intravitreal rTPA.47
Patients with subretinal hemorrhages secondary to AMD 
are psychologically distressed as a result of acute loss of 
Figure 3 submacular hemorrhage of case 3 post treatment.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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vision.48 In our series subretinal r-TPA injection followed by 
gas tamponade allowed the displacement of the hemorrhage 
in all the three cases enabling the follow-up and the further 
treatment of the AMD. No intraoperative or postoperative 
complications were noted.
In conclusion, large subretinal hemorrhage is a possible 
complication of intravitreal anti-VEGF treatment in AMD 
and it may occur days or weeks after the injection. Further 
studies are required for the complete comprehension of the 
mechanism of the pathogenesis.
The surgical approach with vitrectomy, subretinal rTPA 
injection and fluid-gas exchange is a safe and effective 
  treatment. Functional results seem to be positive, especially 
if surgical treatment is promptly performed.
Disclosure
The authors report no conflicts of interest in the work.
References
  1.  Goverdhan SV , Lochhead J. Submacular hemorrhages after intra-
vitreal bevacizumab for large occult choroidal neovascularisation 
in age-related macular degeneration. Br J Ophthalmol. 2008;92: 
210–212.
  2.  Olivier S, Chow DR, Packo KH, MacCumber MW, Awh CC.   
Subretinal recombinant tissue plasminogen activator injection and 
  pneumatic displacement of thick submacular hemorrhage in Age-
Related macular degeneration. Ophthalmology. 2004;111:1201–1208. 
Erratum in:   Ophthalmology. 2004;111:1640.
  3.  Poliner LS, Olk RJ, Burgess D, Gordon ME. Natural history of retinal 
pigment epithelial detachments in age-related macular degeneration. 
Ophthalmology. 1986;93:543–551.
  4.  Theodossiadis GP, Panagiotidis D, Georgalas IG, Moschos M, 
Theodossiadis PG. Retinal hemorrhage after photodynamic therapy 
in patients with subfoveal choroidal neovascularization caused by 
age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 
2003;241:13–18.
  5.  Arnold JJ, Blinder KJ, Bressler NM, et al. Acute severe visual acuity 
decrease after photodynamic therapy with verteporfin: case reports from 
randomized clinical trials TAP and VIP report no. 3. Am J Ophthalmol. 
2004;137:683–696.
  6.  Gelisken F, Inhoffen W, Karim-Zoda K, et al. Subfoveal hemorrhage 
after verteporfin photodynamic therapy in treatment of choroidal 
neovascularization. Graefes Arch Clin Exp Ophthalmol. 2005;243: 
198–203.
  7.  Do DV, Bressler NM, Bressler SB. Large submacular hemorrhages 
after verteporfin therapy. Am J Ophthalmol. 2004;137:558–560.
  8.  Chaudhry NA, Lavaque AJ, Tom DE, Liggett PE. Large submacular 
hemorrhage following PDT with verteporfin in patients with occult 
CNVM secondary to age-related macular degeneration. Ophthalmic 
Surg Lasers Imaging. 2007;38:64–68.
  9.  Matsushita S, Naito T, Takebayashi M, Sato H, Shiota H. The progno-
sis of cases with massive subretinal hemorrhage after photodynamic 
therapy. J Med Invest. 2008;55:231–235.
  10.  Karagiannis DA, Ladas ID, Parikakis E, et al. Changing from bevaci-
zumab to ranibizumab in age-related macular degeneration. Is it safe? 
Clin Interv Aging. 2009;4:457–461.
  11.  Honda S, Hirabayashi H, Tsukahara Y, Negi A. Acute contraction of the 
proliferative membrane after an intravitreal injection of   bevacizumab 
for advanced retinopathy of prematurity. Graefes Arch Clin Exp 
  Ophthalmol. 2008;246:1061–1063.
  12.  Gibran SK, Sachdev A, Stappler T, Newsome R, Wong D, Hiscott P. 
Histological findings of a choroidal neovascular membrane removed 
at the time of macular translocation in a patient previously treated 
with intravitreal bevacizumab treatment (Avastin). Br J Ophthalmol. 
2007;91:602–604.
  13.  Ghassemifar R, Lai CM, Rakoczy PE. VEGF differentially regulates 
transcription and translation of ZO-1alpha+ and ZO-1alpha- and medi-
ates trans-epithelial resistance in cultured endothelial and epithelial 
cells. Cell Tissue Res. 2005;323;117–125.
  14.  Peng S, Adelman RA, Rizzolo LJ. Minimal effects of VEGF and anti-
VEGF drugs on the permeability or selectivity of RPE tight junctions. 
Invest Ophthalmol Vis Sci. 2010;51:3216–3225.
  15.  Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors 
involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell 
Biol. 2009;21:154–165.
  16.  Ziemssen F, Heiduschka P, Peters S, Grisanti S, Schraermeyer U. 
Chances and risks of anti-VEGF therapy. Klin Monbl Augenheilkd. 
2008;225:770–778.
  17.  Schmidt-Erfurth U. Clinical safety of ranibizumab in age-related 
macular degeneration. Expert Opin Drug Saf. 2010;9:149–165.
  18.  Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovas-
cular age-related macular degeneration. N Engl J Med. 2006;355: 
1419–1431.
  19.  Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; 
ANCHOR Study Group. Ranibizumab versus verteporfin photody-
namic therapy for neovascular age-related macular degeneration: 
Two-year results of the ANCHOR study. Ophthalmology. 2009;116:   
57–65.
  20.  Schmidt-Erfurth U. Clinical safety of ranibizumab in age-related 
macular degeneration. Expert Opin Drug Saf. 2010;9(1):149–165.
  21.  Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. 
A Phase IIIb study to evaluate the safety of ranibizumab in subjects 
with neovascular age-related macular degeneration. Ophthalmology. 
2009;116:1731–1739.
  22.  Ziemssen F, Bartz-Schmidt KU, Grisanti S. (Side) effects of VEGF 
inhibition. Ophthalmologe. 2006;103:484–492.
  23.  Baeteman C, Hoffart L, Galland F, Ridings B, Conrath J. Subretinal 
hemorrhage after intravitreal injection of anti-VEGF for age-related 
macular degeneration: a retrospective study. J Fr Ophtalmol. 2009; 
32:309–313.
  24.  Tilanus MA, Vaandrager W, Cuypers MH, Verbeek AM, Hoyng CB. 
Relationship between anticoagulant medication and massive intraocular 
hemorrhage in age-related macular degeneration. Graefes Arch Clin 
Exp Ophthalmol. 2000;238:482–485.
  25.  Kiernan DF, Hariprasad SM, Rusu IM, Mehta SV, Mieler WF, 
Jager RD. Epidemiology of the association between anticoagulants 
and intraocular hemorrhage in patients with neovascular age-related 
macular   degeneration. Retina. 2010;30:1573–1578.
  26.  Iguchi Y, Ito Y, Kikuchi M, et al. Seasonal variations of acute 
  massive submacular hemorrhage associated with age-related macular 
  degeneration. Br J   Ophthalmol. 2006;90:1256–1258.
  27.  Grossniklaus HE, Wilson DJ, Bressler SB, et al. Clinicopathologic 
studies of eyes that were obtained postmortem from four patients who 
were enrolled in the submacular surgery trials: SST Report No. 16.   
Am J Ophthalmol. 2006;141:93–104.
  28.  Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits. 
Am J Ophthalmol. 1982;94:762–773.
  29.  Bhisitkul RB, Winn BJ, Lee OT, et al. Neuroprotective effect of intravit-
real triamcinolone acetonide against photoreceptor apoptosis in a rabbit 
model of subretinal hemorrhage. Invest Ophthalmol Vis Sci. 2008;49(9): 
4071–4077.
  30.  Daneshvar H, Kertes PJ, Leonard BC, Peyman GA. Management of 
submacular hemorrhage with intravitreal sulfurhexafluoride: a pilot 
study. Can J Ophthalmol. 1999;34:385–388.
  31.  Ohji M, Saito Y, Hayashi A, Lewis JM, Tano Y. Pneumatic displace-
ment of subretinal hemorrhage without tissue plasminogen activator. 
Arch Ophthalmol. 1998;116:1326–1332.Clinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
463
subretinal rTPA for subretinal hemorrhage
  32.  Peyman GA, Nelson NC Jr, Alturki W, et al. Tissue plasminogen acti-
vating factor assisted removal of subretinal hemorrhage. Ophthalmic 
Surg. 1991;22:575–582.
  33.  Lim JI, Drews-Botsch C, Sternberg P, Capone A, Aaberg TM. 
  Submacular hemorrhage removal. Ophthalmology. 1995;102: 
1393–1399.
  34.  Scheider A, Gundisch O, Kampik A. Surgical extraction of subfoveal 
choroidal new vessels and submacular hemorrhage in age-related 
macular degeneration: results of a prospective study. Graefes Arch 
Clin Exp Ophthalmol. 1999;237:10–15.
  35.  Lewis H. Intraoperative fibrinolysis of submacular hemorrhage with 
tissue plasminogen activator and surgical drainage. Am J Ophthalmol. 
1994;118:559–568.
  36.  Yang PM, Kuo HK, Kao ML, Chen YJ, Tsai HH. Pneumatic displace-
ment of a dense submacular hemorrhage with or without tissue plas-
minogen activator. Chang Gung Med J. 2005;28(12):852–859.
  37.  Thompson JT, Sjaarda RN. Vitrectomy for the treatment of submacular 
hemorrhages from macular degeneration: a comparison of submacular 
hemorrhage/membrane removal and submacular tissue plasminogen 
activator-assisted pneumatic displacement. Trans Am Ophthalmol Soc. 
2005;103:98–107; discussion 107.
  38.  Kamei M, Tano Y. Tissue plasminogen activator-assisted vitrectomy: 
surgical drainage of submacular hemorrhage. Dev Ophthalmol. 2009;44: 
82–88.
  39.  Hassan AS, Johnson MW, Schneiderman TE, et al. Management of 
submacular hemorrhage with intravitreous tissue plasminogen activa-
tor injection and pneumatic displacement. Ophthalmology. 1999;106: 
1900–1906.
  40.  Ratanasukon M, Kittantong A. Results of intravitreal tissue plasminogen 
activator and expansile gas injection for submacular hemorrhage in 
Thais. Eye (Lond). 2005;19:1328–1332.
  41.  Chen CY, Hooper C, Chiu D, Chamberlain M, Karia N, Heriot WJ.   
Management of submacular hemorrhage with intravitreal injec-
tion of tissue plasminogen activator and expansile gas. Retina. 
2007;27:321–328.
  42.  Haupert CL, McCuen BW, Jaffe GJ, et al. Pars plana vitrectomy, sub-
retinal injection of tissue plasminogen activator, and fluid-gas exchange 
for displacement of thick submacular hemorrhage in age-related macular 
degeneration. Am J Ophthalmol. 2001;131:208–215.
  43.  Kamei M, Tano Y, Maeno T, Ikuno Y, Mitsuda H, Yuasa T. Surgical 
removal of submacular hemorrhage using tissue plasminogen activator 
and perfluorocarbon liquid. Am J Ophthalmol. 1996;121:267–275.
  44.  Stifter E, Michels S, Prager F, et al. Intravitreal bevacizumab therapy 
for neovascular age-related macular degeneration with large submacular 
hemorrhage. Am J Ophthalmol. 2007;144:886–892.
  45.  Meyer CH, Scholl HP, Eter N, Helb HM, Holz FG. Combined treatment 
of acute subretinal hemorrhages with intravitreal recombined tissue 
plasminogen activator, expansile gas and bevacizumab: a retrospective 
pilot study. Acta Ophthalmol. 2008;86:490–494.
  46.  Treumer F, Klatt C, Roider J, Hillenkamp J. Subretinal co-application of 
recombinant tissue plasminogen activator and bevacizumab for neovas-
cular age-related macular degeneration with submacular   hemorrhage. 
Br J Ophthalmol. 2010;94:48–53.
  47.  Hillenkamp J, Surguch V, Framme C, Gabel VP, Sachs HG.   
Management of submacular hemorrhage with intravitreal versus sub-
retinal injection of recombinant tissue plasminogen activator. Graefes 
Arch Clin Exp Ophthalmol. 2010;248:5–11.
  48.  Mozaffarieh M, Sacu S, Benesch T, Wedrich A. Subretinal hemor-
rhages secondary to age-related macular degeneration:   psychological 
and vision-related functional perspectives. Ophthalmologica. 
2008;222:199–204.